Biomarkers in Nonalcoholic Fatty Liver Disease
BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is a chronic liver condition characterized by insulin resistance, type 2 diabetes and fat accumulation in the liver that may cause hepatic inflammation and progressive scarring leading to nonalcoholic steatohepatitis (NASH) and irreversible liver...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | Canadian Journal of Gastroenterology and Hepatology |
| Online Access: | http://dx.doi.org/10.1155/2014/757929 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850173113059246080 |
|---|---|
| author | Manuela G Neuman Lawrence B Cohen Radu M Nanau |
| author_facet | Manuela G Neuman Lawrence B Cohen Radu M Nanau |
| author_sort | Manuela G Neuman |
| collection | DOAJ |
| description | BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is a chronic liver condition characterized by insulin resistance, type 2 diabetes and fat accumulation in the liver that may cause hepatic inflammation and progressive scarring leading to nonalcoholic steatohepatitis (NASH) and irreversible liver damage (cirrhosis). As a result, there has been increased recognition of the need to assess and closely monitor individuals for risk factors of components of NAFLD and NASH, as well as the severity of these conditions using biomarkers. |
| format | Article |
| id | doaj-art-d183752f1170439fab66b0ce1e7e5d1e |
| institution | OA Journals |
| issn | 2291-2789 2291-2797 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Gastroenterology and Hepatology |
| spelling | doaj-art-d183752f1170439fab66b0ce1e7e5d1e2025-08-20T02:19:55ZengWileyCanadian Journal of Gastroenterology and Hepatology2291-27892291-27972014-01-01281160761810.1155/2014/757929Biomarkers in Nonalcoholic Fatty Liver DiseaseManuela G Neuman0Lawrence B Cohen1Radu M Nanau2In Vitro Drug Safety and Biotechnology, Faculty of Medicine, University of Toronto, CanadaDivision of Gastroenterology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, CanadaIn Vitro Drug Safety and Biotechnology, Faculty of Medicine, University of Toronto, CanadaBACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is a chronic liver condition characterized by insulin resistance, type 2 diabetes and fat accumulation in the liver that may cause hepatic inflammation and progressive scarring leading to nonalcoholic steatohepatitis (NASH) and irreversible liver damage (cirrhosis). As a result, there has been increased recognition of the need to assess and closely monitor individuals for risk factors of components of NAFLD and NASH, as well as the severity of these conditions using biomarkers.http://dx.doi.org/10.1155/2014/757929 |
| spellingShingle | Manuela G Neuman Lawrence B Cohen Radu M Nanau Biomarkers in Nonalcoholic Fatty Liver Disease Canadian Journal of Gastroenterology and Hepatology |
| title | Biomarkers in Nonalcoholic Fatty Liver Disease |
| title_full | Biomarkers in Nonalcoholic Fatty Liver Disease |
| title_fullStr | Biomarkers in Nonalcoholic Fatty Liver Disease |
| title_full_unstemmed | Biomarkers in Nonalcoholic Fatty Liver Disease |
| title_short | Biomarkers in Nonalcoholic Fatty Liver Disease |
| title_sort | biomarkers in nonalcoholic fatty liver disease |
| url | http://dx.doi.org/10.1155/2014/757929 |
| work_keys_str_mv | AT manuelagneuman biomarkersinnonalcoholicfattyliverdisease AT lawrencebcohen biomarkersinnonalcoholicfattyliverdisease AT radumnanau biomarkersinnonalcoholicfattyliverdisease |